Clinical utility of non-invasive tests to predict clinical outcomes in non-alcoholic fatty liver disease

查看全文 作　　者：Shi Yan [1]Lee;Darren [2]J.H.Tan;Wen Hui [2]Lim;Cheng Han [1]Ng;Mark [1,2,3]Muthiah;Daniel [1,2,3]Q.Huang 机构地区：[1]Division of Gastroenterology and Hepatology,Department of Medicine,National University Hospital,Singapore,Singapore;[2]Yong Loo Lin School of Medicine,National University of Singapore,Singapore,Singapore;[3]National University Centre for Organ Transplantation,National University Health System,Singapore,Singapore 出　　处：《Hepatobiliary Surgery and Nutrition》索引2023年第12卷第6期,共3页 基　　金：support from the Singapore Ministry of Health’s National Medical Research Council (No.MOH-001370 to DQH). 摘　　要：Non-alcoholic fatty liver disease(NAFLD)is the leading cause of chronic liver disease,and the fastest-growing cause of hepatocellular carcinoma(HCC)worldwide(1,2).As the number of people with NAFLD is too great to perform surveillance in all,risk-stratification strategies are increasingly important to identify those at the highest risk of decompensation and HCC(3,4). 关 键 词：Non-alcoholic fatty liver disease(NAFLD) non-invasive tests fibrosis-4(FIB-4) vibration-controlled transient elastography(VCTE) clinical outcomes